ArtivaBio

Artiva Biotherapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference. Management will take part in both a panel and a fireside chat. A live audio webcast and archived replay will be available through the Investors section of Artiva’s website. See the press release for more details: investors.artivabio.com/News-and-Event… $ARTV

At the 11th Innate Killer Summit, Artiva Biotherapeutics will discuss progress in developing AlloNK® for autoimmune disease, with a focus on deep B-cell depletion and how advanced therapies can be developed in ways that support real-world care. Artiva’s approach with AlloNK considers not only treatment effect and durability, but also how therapies can be manufactured consistently, scaled efficiently, and delivered in outpatient settings where many autoimmune patients receive care. If you are attending the Innate Killer Summit, join us for these sessions: Tuesday, March 24 | 4:00 pm Panel: 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗣𝗮𝘁𝗵𝘄𝗮𝘆𝘀 𝗳𝗿𝗼𝗺 𝗔𝘂𝘁𝗼𝗹𝗼𝗴𝗼𝘂𝘀 𝘁𝗼 𝗔𝗹𝗹𝗼𝗴𝗲𝗻𝗲𝗶𝗰 𝘁𝗼 𝗜𝗻 𝗩𝗶𝘃𝗼, with Chris Horan, Chief Technical Operations Officer Wednesday, March 25 | 12:30 pm Presentation: 𝗔𝗹𝗹𝗼𝗡𝗞 𝗶𝗻 𝗔𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲: 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀 & 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀, with Nick Veomett, Ph.D., VP, Corporate Development & AlloNK® Program Lead See the full agenda: innate-killer.com

Artiva Biotherapeutics reported full year 2025 financial results and recent progress advancing AlloNK® in autoimmune disease. In the first half of 2026, initial clinical response data from at least 15 refractory RA patients are expected, alongside a planned FDA interaction to discuss potential pivotal trial design. Highlights from 2025 include continued enrollment across autoimmune trials, demonstration of deep and consistent B-cell depletion supporting the intended mechanism of action, and FDA Fast Track designation for AlloNK in refractory rheumatoid arthritis. See the press release for more: investors.artivabio.com/News-and-Event… $ARTV

Many available therapies for rheumatoid arthritis fail to control disease over time, highlighting a deeper challenge in treating immune dysfunction. On the 𝗕𝗮𝘀𝗲 𝘁𝗼 𝗕𝗮𝘀𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗣𝗼𝗱𝗰𝗮𝘀𝘁, Artiva’s Lisa Guerrettaz discusses how B-cell depletion with AlloNK is shaping a new therapeutic approach for autoimmune diseases. Listen here for more: rss.com/podcasts/base-…

Artiva will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference to discuss our clinical progress with AlloNK®, one of the most advanced B-cell depletion approaches in autoimmune disease. With efficacy data and important regulatory discussions anticipated in the first half of this year, we are focused on bringing AlloNK into broader clinical use. Despite current therapies, millions of patients still live with uncontrolled autoimmune disease. We believe the ability of AlloNK to pair deep, antibody-enabled B-cell depletion with a scalable, outpatient-ready format has the potential to meaningfully raise the standard of care. Read the release for more details, including webcast information: investors.artivabio.com/News-and-Event… $ARTV #rheumatoidarthritis #autoimmunedisease #clinicaltrials #AlloNK #Bcelldepletion

Today we announced the appointment of Thad Huston as Chief Financial Officer as Artiva enters an important stage of development. We anticipate sharing clinical efficacy data for AlloNK® in rheumatoid arthritis and continue our regulatory engagement in the first half of this year as we advance a scalable B-cell depletion immunotherapy for autoimmune diseases. Incomplete B-cell depletion can leave patients with persistent disease activity and ongoing treatment burden. AlloNK is intended to enhance antibody-driven B-cell clearance and deliver deep depletion in an outpatient setting, with the scalability required for broad access. The goal is clear: immune reset, delivered in a format that can reach more patients. As we enter our next stage of development, we are excited to welcome Thad, who brings more than three decades of global financial leadership experience. He has guided companies through critical development milestones and built the foundation needed to move innovation from clinical promise to real-world access. Read the release for more: investors.artivabio.com/News-and-Event… $ARTV #rheumatoidarthritis #autoimmunedisease #clinicaltrials #AlloNK #Bcelldepletion

We are pleased to announce the appointment of Elaine Sorg to Artiva’s Board of Directors. Ms. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry, including leading the commercialization of major immunology therapies such as HUMIRA® and RINVOQ® for rheumatoid arthritis. As we prepare to share clinical activity data from our AlloNK® regimen in rheumatoid arthritis and engage with the FDA on a registrational trial, Elaine’s experience building and scaling biopharmaceutical companies and launching innovative therapies will provide valuable strategic guidance. We look forward to her contributions as we continue advancing AlloNK, designed to enable deep B-cell depletion and potentially offer a differentiated treatment profile in rheumatoid arthritis and other autoimmune diseases. Read the full announcement here: investors.artivabio.com/News-and-Event… #ARTV #AlloNK #autoimmunedisease #immunology

At the 2026 Tandem Meetings, we presented two posters that together reinforce the broader potential of AlloNK®. Updated clinical data in relapsed or refractory non-Hodgkin lymphoma continue to demonstrate deep B-cell depletion and durable responses with AlloNK® in combination with rituximab, delivered in an outpatient setting and without gene modification. We also shared pharmacoeconomic data indicating that an AlloNK®-based regimen may be administered with substantially lower non-drug healthcare costs compared to published reports of autologous CAR T, with no hospitalizations required for adverse event management in the evaluated cohort. Taken together, these data support our strategy to advance AlloNK® in autoimmune disease as a scalable, outpatient-ready immunology platform designed to align with real-world care. We thank the investigators, study teams, and patients who make this work possible. To see our posters, visit: investors.artivabio.com/News-and-Event… #AlloNK #NKcell #NKcells #NKcelltherapy #autoimmunedisease #immunology #clinicaldevelopment

At Advanced Therapies Week 2026, Artiva Biotherapeutics will discuss the central challenge in autoimmune disease, how to deliver deeper, more durable disease control in ways that are scalable, accessible, and aligned with real-world care. phacilitate.com/advanced-thera…

Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Tandem Meetings Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL investors.artivabio.com/News-and-Event… $ARTV

Thank you to the patients, investigators, partners, and team who supported us in 2025 and made it a year of meaningful clinical progress. We look ahead to 2026 with focus and momentum as we advance #AlloNK for the treatment of refractory rheumatoid arthritis.

We are in Philadelphia this week for the 𝟯𝗿𝗱 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗳𝗼𝗿 𝗔𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗦𝘂𝗺𝗺𝗶𝘁 discussing the latest #AlloNK data for B-cell depletion to treat diverse #autoimmunediseases in the community setting. cell-therapy-autoimmune-disease.com

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease Join today’s 8 am ET webcast: investors.artivabio.com/News-and-Event… $ARTV #AlloNK

Artiva reported Q3 2025 results. Join today’s 8 am ET webcast for initial safety and translational data for AlloNK® in combination with anti-CD20 monoclonal antibodies across autoimmune diseases. investors.artivabio.com/News-and-Event… $ARTV #AlloNK

Our CFO and EVP, Corporate Development joined The BioHub Podcast to discuss her path from Wall Street to biotech operations and what drew her to Artiva’s mission to make advanced immunotherapies broadly accessible. Watch here: youtu.be/Ct6b9EBMpR0

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK® See the release for more details and to register: investors.artivabio.com/News-and-Event… $ARTV #AlloNK #autoimmunedisease

Artiva Biotherapeutics will participate in two upcoming investor conferences in November. Read the release for more info: investors.artivabio.com/News-and-Event… $ARTV #JefferiesHealthcare #AlloNK #NKcelltherapy #autoimmunedisease

Artiva Biotherapeutics announces Fast Track Designation for #AlloNK in refractory RA, refractory rheumatoid arthritis as lead indication, and timing for upcoming data release. investors.artivabio.com/News-and-Event… $ARTV #autoimmunedisease

Nicholas Veomett, Ph.D., Artiva’s VP, Corporate Development, will present at the 𝗖𝗲𝗹𝗹 𝗮𝗻𝗱 𝗚𝗲𝗻𝗲 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗲𝘀𝗮 on the latest on #AlloNK for the potential treatment of #autoimmunediseases. meetingonthemesa.com #CGMesa25 #NKcelltherapy